

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

Gerhard Siemeister et al.

Group Art Unit: 1635

Serial No.: 09/887,527

Examiner: J. E. ANGELL

Filed: June 25, 2001

For: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF
AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE

#16/K.T.
6/26
Elect.
RECEIVED

JUN 25 2003

TECH CENTER 1600/2900

REPLY TO RESTRICTION

Commissioner for Patents
Washington, D.C. 20231

Sir:

This communication is responsive to the office action dated June 3, 2003.


In response to the restriction requirement, applicants elect Group I (claims 1-7 and 9-11), with traverse. With respect to the election of a subgroup, applicants elect Group A (claims 1-7 and 9-11 drawn to a pharmaceutical composition comprising a compound, which inhibits or interferes with VEGF/VEGF), Group i) (drawn to a small molecular weight substance), and Groups a) (SEQ ID NO:60) and b) ((4-chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate).

The Examiner is urged to withdraw the restriction requirement/election because an examination of the full scope of the claims would not represent a serious search burden for the patent office. Absent a serious burden of examination, restriction is not proper. See M.P.E.P. § 803. Thus, the requirement should be withdrawn.


SCH-1815

No fee is believed to be due with this response, however, the Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano (Reg. No. 27,969)
Attorney for Applicant(s)



Nicole E. Kinsey (Reg. No. 50,723)
Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201

Filed: June 24, 2003

K:\SCH\1815\07-03-03 REPLY TO RESTRICTION.DOC

SCH-1815